Epidemiology and Control of Mansonella Perstans Infection in Uganda - Full Text View

Sponsors and Collaborators:	DBL -Institute for Health Research and Development Vector control Division, Kampala, Uganda
Information provided by:	DBL -Institute for Health Research and Development
ClinicalTrials.gov Identifier:	NCT00215280

Purpose

Mansonella perstans (M. perstans) infection is widespread in Uganda. Knowledge about the epidemiology of this infection, and of the morbidity it induces is poor, and no effective treatment is available. The study aims at providing data on diagnostic, epidemiological, morbidity and treatment aspects of M.

perstans infections in Uganda.

Condition	Intervention
Mansonelliasis Pruritus Lymphoedema Abdominal Pains	Drug: ivermectin and albendazole

Study Type:	Interventional
Study Design:	Treatment, Randomized, Double-Blind, Placebo Control, Single Group Assignment, Safety/Efficacy Study
Official Title:	Studies on the Epidemiology and Control of Mansonella Perstans Infection in Uganda

Resource links provided by NLM:

Genetics Home Reference related topics: lymphedema-distichiasis syndrome

MedlinePlus related topics: Abdominal Pain Itching Lymphedema

Drug Information available for: Albendazole Ivermectin

U.S. FDA Resources

Further study details as provided by DBL -Institute for Health Research and Development:

Primary Outcome Measures:

microfilariae periodicity patterns
epidemiology of M. perstans at community level
clinical spectre among infected
reduction in microfilaraemia

Secondary Outcome Measures:

treatment effect on clinical manifestations

Estimated Enrollment:	1000
Study Start Date:	November 2005
Estimated Study Completion Date:	February 2006

Detailed Description:

Overall objective: to investigate diagnostic, epidemiological and treatment aspects of M. perstans in Uganda with relevance to control

Specific objectives:

To establish the pattern of diurnal periodicity of M. perstans microfilaraemia in humans
To establish the patterns of M. perstans microfilaraemia and possible clinical manifestations related to this infection in two communities with medium to high endemicity
To determine the efficacy of ivermectin alone and the combination of ivermectin and albendazole on M. perstans microfilaraemia.

Eligibility

Ages Eligible for Study:	5 Years and older
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	Yes

Criteria

Inclusion Criteria:

Individuals >= 5 years with or without M. perstans infection

Exclusion Criteria:

Individuals < 5 years
Pregnant women

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00215280

Locations

Uganda, Luwero and Mukono Districts
Luwero
Luwero and Mukono, Luwero and Mukono Districts, Uganda

Sponsors and Collaborators

DBL -Institute for Health Research and Development

Vector control Division, Kampala, Uganda

Investigators

Principal Investigator:

Asanta M Asio, Msc

Vector control Division, Kampala, Uganda

More Information

Additional Information:

Related Info This link exits the ClinicalTrials.gov site

No publications provided by DBL -Institute for Health Research and Development

Additional publications automatically indexed to this study by National Clinical Trials Identifier (NCT ID):

Asio SM, Simonsen PE, Onapa AW. A randomised, double-blind field trial of ivermectin alone and in combination with albendazole for the treatment of Mansonella perstans infections in Uganda. Trans R Soc Trop Med Hyg. 2009 Mar;103(3):274-9. Epub 2008 Dec 9.

Asio SM, Simonsen PE, Onapa AW. Mansonella perstans filariasis in Uganda: patterns of microfilaraemia and clinical manifestations in two endemic communities. Trans R Soc Trop Med Hyg. 2009 Mar;103(3):266-73. Epub 2008 Sep 21.

Study ID Numbers:	MV917090205
Study First Received:	September 21, 2005
Last Updated:	April 19, 2007
ClinicalTrials.gov Identifier:	NCT00215280 History of Changes
Health Authority:	Uganda: National Council for Science and Technology

Keywords provided by DBL -Institute for Health Research and Development:

Mansonella perstans
microfilaraemia
ivermectin

albendazole
Uganda
microfilaraemia

Study placed in the following topic categories:

Pruritus
Signs and Symptoms, Digestive
Abdominal Pain
Dipetalonema Infections
Filariasis
Anthelmintics
Pain
Nematode Infections
Antimitotic Agents
Albendazole

Lymphedema
Signs and Symptoms
Lymphatic Diseases
Mansonelliasis
Ivermectin
Tubulin Modulators
Parasitic Diseases
Acanthocheilonemiasis
Helminthiasis

Additional relevant MeSH terms:

Anti-Infective Agents
Antiprotozoal Agents
Molecular Mechanisms of Pharmacological Action
Signs and Symptoms, Digestive
Antineoplastic Agents
Abdominal Pain
Filariasis
Pain
Albendazole
Signs and Symptoms
Antiparasitic Agents
Mansonelliasis
Ivermectin
Therapeutic Uses
Parasitic Diseases

Helminthiasis
Antiplatyhelmintic Agents
Mitosis Modulators
Dipetalonema Infections
Nematode Infections
Anthelmintics
Antimitotic Agents
Pharmacologic Actions
Anticestodal Agents
Lymphedema
Spirurida Infections
Lymphatic Diseases
Tubulin Modulators
Secernentea Infections

ClinicalTrials.gov processed this record on July 06, 2009